COVID-19, asthma, and biological therapies: What we need to know

Mário Morais-Almeida; Rita Aguiar; Bryan Martin; Ignacio J. Ansotegui; Motohiro Ebisawa; L. Karla Arruda; Marco Caminati; Giorgio Walter Canonica; Tara Carr; Geoffrey Chupp; Jonathan Corren; Ignacio Dávila; Hae Sim Park; Nicola A. Hanania; Lanny Rosenwasser; Mario Sánchez-Borges; J. Christian Virchow; Anahí Yáñez; Jonathan A. Bernstein; Luis Caraballo; Yoon Seok Chang; Manana Chikhladze; Alessandro Fiocchi; Sandra N. González-Diaz; Luciana Kase Tanno; Michael Levin; Jose António Ortega-Martell; Giovanni Passalacqua; David B. Peden; Philip W. Rouadi; James L. Sublett; Gary W.K. Wong; Eugene R. Bleecker

doi:10.1016/j.waojou.2020.100126

COVID-19, asthma, and biological therapies: What we need to know

Mário Morais-Almeida, Rita Aguiar, Bryan Martin, Ignacio J. Ansotegui, Motohiro Ebisawa, L. Karla Arruda, Marco Caminati, Giorgio Walter Canonica, Tara Carr, Geoffrey Chupp, Jonathan Corren, Ignacio Dávila, Hae Sim Park, Nicola A. Hanania, Lanny Rosenwasser, Mario Sánchez-Borges, J. Christian Virchow, Anahí Yáñez, Jonathan A. Bernstein, Luis CaraballoYoon Seok Chang, Manana Chikhladze, Alessandro Fiocchi, Sandra N. González-Diaz, Luciana Kase Tanno, Michael Levin, Jose António Ortega-Martell, Giovanni Passalacqua, David B. Peden, Philip W. Rouadi, James L. Sublett, Gary W.K. Wong, Eugene R. Bleecker

Medicine

Research output: Contribution to journal › Review article › peer-review

91 Scopus citations

Abstract

Managing patients with severe asthma during the coronavirus pandemic and COVID-19 is a challenge. Authorities and physicians are still learning how COVID-19 affects people with underlying diseases, and severe asthma is not an exception. Unless relevant data emerge that change our understanding of the relative safety of medications indicated in patients with asthma during this pandemic, clinicians must follow the recommendations of current evidence-based guidelines for preventing loss of control and exacerbations. Also, with the absence of data that would indicate any potential harm, current advice is to continue the administration of biological therapies during the COVID-19 pandemic in patients with asthma for whom such therapies are clearly indicated and have been effective. For patients with severe asthma infected by SARS-CoV-2, the decision to maintain or postpone biological therapy until the patient recovers should be a case-by-case based decision supported by a multidisciplinary team. A registry of cases of COVID-19 in patients with severe asthma, including those treated with biologics, will help to address a clinical challenge in which we have more questions than answers.

Original language	English (US)
Article number	100126
Journal	World Allergy Organization Journal
Volume	13
Issue number	5
DOIs	https://doi.org/10.1016/j.waojou.2020.100126
State	Published - May 2020

Keywords

Asthma
Biologics
COVID-19
Pandemic
SARS-CoV-2
Severe
Treatment

ASJC Scopus subject areas

Immunology and Allergy
Immunology
Pulmonary and Respiratory Medicine

Access to Document

10.1016/j.waojou.2020.100126

Cite this

Morais-Almeida, M., Aguiar, R., Martin, B., Ansotegui, I. J., Ebisawa, M., Arruda, L. K., Caminati, M., Canonica, G. W., Carr, T., Chupp, G., Corren, J., Dávila, I., Park, H. S., Hanania, N. A., Rosenwasser, L., Sánchez-Borges, M., Virchow, J. C., Yáñez, A., Bernstein, J. A., ... Bleecker, E. R. (2020). COVID-19, asthma, and biological therapies: What we need to know. World Allergy Organization Journal, 13(5), Article 100126. https://doi.org/10.1016/j.waojou.2020.100126

Morais-Almeida, M, Aguiar, R, Martin, B, Ansotegui, IJ, Ebisawa, M, Arruda, LK, Caminati, M, Canonica, GW, Carr, T, Chupp, G, Corren, J, Dávila, I, Park, HS, Hanania, NA, Rosenwasser, L, Sánchez-Borges, M, Virchow, JC, Yáñez, A, Bernstein, JA, Caraballo, L, Chang, YS, Chikhladze, M, Fiocchi, A, González-Diaz, SN, Tanno, LK, Levin, M, Ortega-Martell, JA, Passalacqua, G, Peden, DB, Rouadi, PW, Sublett, JL, Wong, GWK & Bleecker, ER 2020, 'COVID-19, asthma, and biological therapies: What we need to know', World Allergy Organization Journal, vol. 13, no. 5, 100126. https://doi.org/10.1016/j.waojou.2020.100126

@article{b5651a97eb9c458cb7ffab22408ce6fc,

title = "COVID-19, asthma, and biological therapies: What we need to know",

abstract = "Managing patients with severe asthma during the coronavirus pandemic and COVID-19 is a challenge. Authorities and physicians are still learning how COVID-19 affects people with underlying diseases, and severe asthma is not an exception. Unless relevant data emerge that change our understanding of the relative safety of medications indicated in patients with asthma during this pandemic, clinicians must follow the recommendations of current evidence-based guidelines for preventing loss of control and exacerbations. Also, with the absence of data that would indicate any potential harm, current advice is to continue the administration of biological therapies during the COVID-19 pandemic in patients with asthma for whom such therapies are clearly indicated and have been effective. For patients with severe asthma infected by SARS-CoV-2, the decision to maintain or postpone biological therapy until the patient recovers should be a case-by-case based decision supported by a multidisciplinary team. A registry of cases of COVID-19 in patients with severe asthma, including those treated with biologics, will help to address a clinical challenge in which we have more questions than answers.",

keywords = "Asthma, Biologics, COVID-19, Pandemic, SARS-CoV-2, Severe, Treatment",

author = "M{\'a}rio Morais-Almeida and Rita Aguiar and Bryan Martin and Ansotegui, {Ignacio J.} and Motohiro Ebisawa and Arruda, {L. Karla} and Marco Caminati and Canonica, {Giorgio Walter} and Tara Carr and Geoffrey Chupp and Jonathan Corren and Ignacio D{\'a}vila and Park, {Hae Sim} and Hanania, {Nicola A.} and Lanny Rosenwasser and Mario S{\'a}nchez-Borges and Virchow, {J. Christian} and Anah{\'i} Y{\'a}{\~n}ez and Bernstein, {Jonathan A.} and Luis Caraballo and Chang, {Yoon Seok} and Manana Chikhladze and Alessandro Fiocchi and Gonz{\'a}lez-Diaz, {Sandra N.} and Tanno, {Luciana Kase} and Michael Levin and Ortega-Martell, {Jose Ant{\'o}nio} and Giovanni Passalacqua and Peden, {David B.} and Rouadi, {Philip W.} and Sublett, {James L.} and Wong, {Gary W.K.} and Bleecker, {Eugene R.}",

note = "Publisher Copyright: {\textcopyright} 2020 The Authors",

year = "2020",

month = may,

doi = "10.1016/j.waojou.2020.100126",

language = "English (US)",

volume = "13",

journal = "World Allergy Organization Journal",

issn = "1939-4551",

publisher = "Lippincott Williams and Wilkins",

number = "5",

}

TY - JOUR

T1 - COVID-19, asthma, and biological therapies

T2 - What we need to know

AU - Morais-Almeida, Mário

AU - Aguiar, Rita

AU - Martin, Bryan

AU - Ansotegui, Ignacio J.

AU - Ebisawa, Motohiro

AU - Arruda, L. Karla

AU - Caminati, Marco

AU - Canonica, Giorgio Walter

AU - Carr, Tara

AU - Chupp, Geoffrey

AU - Corren, Jonathan

AU - Dávila, Ignacio

AU - Park, Hae Sim

AU - Hanania, Nicola A.

AU - Rosenwasser, Lanny

AU - Sánchez-Borges, Mario

AU - Virchow, J. Christian

AU - Yáñez, Anahí

AU - Bernstein, Jonathan A.

AU - Caraballo, Luis

AU - Chang, Yoon Seok

AU - Chikhladze, Manana

AU - Fiocchi, Alessandro

AU - González-Diaz, Sandra N.

AU - Tanno, Luciana Kase

AU - Levin, Michael

AU - Ortega-Martell, Jose António

AU - Passalacqua, Giovanni

AU - Peden, David B.

AU - Rouadi, Philip W.

AU - Sublett, James L.

AU - Wong, Gary W.K.

AU - Bleecker, Eugene R.

PY - 2020/5

Y1 - 2020/5

N2 - Managing patients with severe asthma during the coronavirus pandemic and COVID-19 is a challenge. Authorities and physicians are still learning how COVID-19 affects people with underlying diseases, and severe asthma is not an exception. Unless relevant data emerge that change our understanding of the relative safety of medications indicated in patients with asthma during this pandemic, clinicians must follow the recommendations of current evidence-based guidelines for preventing loss of control and exacerbations. Also, with the absence of data that would indicate any potential harm, current advice is to continue the administration of biological therapies during the COVID-19 pandemic in patients with asthma for whom such therapies are clearly indicated and have been effective. For patients with severe asthma infected by SARS-CoV-2, the decision to maintain or postpone biological therapy until the patient recovers should be a case-by-case based decision supported by a multidisciplinary team. A registry of cases of COVID-19 in patients with severe asthma, including those treated with biologics, will help to address a clinical challenge in which we have more questions than answers.

AB - Managing patients with severe asthma during the coronavirus pandemic and COVID-19 is a challenge. Authorities and physicians are still learning how COVID-19 affects people with underlying diseases, and severe asthma is not an exception. Unless relevant data emerge that change our understanding of the relative safety of medications indicated in patients with asthma during this pandemic, clinicians must follow the recommendations of current evidence-based guidelines for preventing loss of control and exacerbations. Also, with the absence of data that would indicate any potential harm, current advice is to continue the administration of biological therapies during the COVID-19 pandemic in patients with asthma for whom such therapies are clearly indicated and have been effective. For patients with severe asthma infected by SARS-CoV-2, the decision to maintain or postpone biological therapy until the patient recovers should be a case-by-case based decision supported by a multidisciplinary team. A registry of cases of COVID-19 in patients with severe asthma, including those treated with biologics, will help to address a clinical challenge in which we have more questions than answers.

KW - Asthma

KW - Biologics

KW - COVID-19

KW - Pandemic

KW - SARS-CoV-2

KW - Severe

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=85084835034&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85084835034&partnerID=8YFLogxK

U2 - 10.1016/j.waojou.2020.100126

DO - 10.1016/j.waojou.2020.100126

M3 - Review article

AN - SCOPUS:85084835034

SN - 1939-4551

VL - 13

JO - World Allergy Organization Journal

JF - World Allergy Organization Journal

IS - 5

M1 - 100126

ER -

COVID-19, asthma, and biological therapies: What we need to know

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this